Lubiprostone as a Modulator of Gut Microbial Translocation in HIV With Incomplete CD4 Recovery on Antiretroviral Therapy

NCT01839734 | Completed Phase 2 Results

• 1 other identifier: 13-071
• Study Type: interventional
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

The use of lubiprostone will decrease the levels of immune activation in HIV-infected subjects with incomplete CD4+ T-cell recovery with antiretroviral therapy (ART).

• Lubiprostone will decrease levels of translocated gut microbial products in HIV-infected subjects with incomplete CD4+ T-cell recovery with ART.
• The decrease in levels of translocated gut microbial products will be associated with a decline in the levels of immune activation in HIV-infected subjects with incomplete CD4+ T-cell recovery with ART.

Conditions

HIV

Keywords

CD4+

Outcome Measures

Primary Outcomes (4)

• Changes in Gut Microbial Translocation (iFABP)

  Summary difference of participant's median iFABP MT marker change at week 4 from baseline aggregate median values

  Baseline and 4 weeks

• Changes in Gut Microbial Translocation (Zonulin)

  Summary difference of participant's median Zonulin MT marker change at week 4 from baseline aggregate median values.

  Baseline and 4 weeks

• Changes in Gut Microbial Translocation (sCD14)

  Summary difference of participant's median sCD14 MT marker change at week 4 from baseline aggregate median values

  Baseline and 4 weeks

• Changes in Gut Microbial Translocation (sCD163)

  Summary difference of participant's median sCD163 MT marker change at week 4 from baseline aggregate median values

  Baseline and 4 weeks

Secondary Outcomes (4)

• Changes in Systemic Inflammation (IL-6)

  Baseline and 4 weeks

• Changes in Systemic Inflammation (hsCRP)

  Baseline and 4 weeks

• Changes in Peripheral CD4+

  Baseline and 4 weeks

• Number of Participants With Adverse Events During Study Period

  4 weeks

Study Arms (2)

Lubiprostone

EXPERIMENTAL

4 weeks of treatment with lubiprostone 24 mcg by mouth (PO) once-daily (Interventional Group)

Drug: Lubiprostone

No intervention

NO INTERVENTION

No intervention

Interventions

Lubiprostone DRUG

Lubiprostone 24 mcg by mouth (PO) once-daily

Also known as: Brand name: Amitiza

Lubiprostone

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• HIV-1 infection, documented by any licensed rapid HIV test or HIV enzyme or chemiluminescence immunoassay (E/CIA) test kit at any time prior to study entry and confirmed by Western blot or a second antibody test by a method other than the initial rapid HIV and/or E/CIA, or by HIV-1 antigen, plasma HIV-1 RNA viral load.
• On tenofovir/emtricitabine/efavirenz single tablet combination therapy for at least 72 weeks prior to study entry.
• No plans to change the antiretroviral regimen at least in the next 3 months after study entry.
• CD4+ cell count \< 350 cells/mm3 obtained within 120 days prior to study entry at any laboratory that has a Clinical Laboratory Improvement Amendments (CLIA) certification or its equivalent.
• All previous CD4+ cell counts should be \< 350 cells/mm3 for at least 72 weeks prior to study entry while subjects were on ART.
• Documentation of HIV-1 RNA below the limit of detection (e.g., \< 50 copies/mL on Roche Amplicor HIV-1 Monitor assay, \< 75 copies/mL on the Versant HIV-1 RNA assay by branched DNA, \< 400 copies/mL on a standard Roche Amplicor assay, \< 40 copies/mL on the Abbott m2000sp/m2000rt real-time PCR test, \< 48 copies/mL on the COBAS AmpliPrep/TAQMAN HIV-1 assay) verified by at least two measurements prior to study entry, one of which must be at least 48 weeks prior to study entry and one measurement that was obtained between 121 days and 48 weeks prior to study entry.
• Screening HIV-1 RNA below the limit of detection obtained within 120 days prior to study entry using a FDA -approved assay (e.g., \< 50 copies/mL on Roche Amplicor HIV-1 Monitor assay, \< 75 copies/mL on the Versant HIV-1 RNA assay by branched DNA, \< 40 copies/mL on the Abbott m2000sp/m2000rt real-time PCR test, \< 48 copies/mL on the COBAS AmpliPrep/TAQMAN HIV-1 assay).
• Fasting laboratory values obtained within 45 days prior to entry as follows:
• Absolute neutrophil count (ANC) ≥ 1000/mm3
• Hemoglobin ≥ 10.0 g/dL
• Platelet count ≥ 50,000/mm3
• International normalized ratio (INR)
• Female subjects of reproductive potential (defined as girls who have reached menarche or women who have not been post-menopausal for at least 24 consecutive months; i.e., those who have had menses within the preceding 24 months or have not undergone a sterilization procedure \[hysterectomy, bilateral oophorectomy, bilateral tubal ligation, or bilateral salpingectomy\]) must have a negative serum or urine β-HCG pregnancy test with a sensitivity of at least 50 mIU/mL performed within 24 hours prior to study entry.
• If participating in sexual activity that could lead to pregnancy, the female subject must agree to use one form of contraceptive as listed below while receiving protocol-specified treatment and for 4 weeks after stopping the treatment.
• If the female subject is not of reproductive potential (girls who have not reached menarche, women who have been post-menopausal for at least 24 consecutive months, or women who have undergone surgical sterilization, e.g., hysterectomy, bilateral oophorectomy, or bilateral tubal ligation or salpingectomy), she is eligible without requiring the use of a contraceptive. Self report is acceptable documentation of sterilization, other contraceptive methods, and menopause.

You may not qualify if:

• Active diarrhea (3 or more unformed stools per day) within 28 days prior to study entry (except if site investigator or primary care provider attributes diarrhea to antiretroviral or azithromycin use).
• History of or active inflammatory bowel disease.
• History of significant liver disease, defined as having chronic liver disease (including chronic alcoholic liver disease, hepatitis B or C), plus either: a) ascites, b) encephalopathy, or c) a Child-Pugh Score of \> 7.
• Receipt of antimicrobial therapy within 30 days prior to study entry.
• NOTE: Antimicrobial use for prophylaxis of opportunistic infections, e.g., azithromycin or trimethoprim-sulfamethoxazole, is allowed.
• Active infection requiring the use of antibiotics within 30 days prior to study entry.
• Known allergy/sensitivity or any hypersensitivity to components of study drug or their formulation.
• Serious illness requiring systemic treatment and/or hospitalization within 14 days prior to entry.
• Use of any of the following medications for more than 3 consecutive days within the 60 days prior to study entry:
• Immunosuppressives (e.g., azathioprine, corticosteroids \[physiologic replacement doses are allowed\], cyclosporine, mycophenolate, NSAIDs (nonsteroidal anti-inflammatory drugs), sirolimus, sulfasalazine, tacrolimus)
• Immune modulators (e.g., cytokines \[e.g., IL-2\], granulocyte colony stimulating factor, growth hormone, tumor necrosis factor antagonists, thalidomide)
• Antineoplastic agents
• Probiotics (defined as products that contain significant amounts of live microorganisms and are ingested for specific health benefits, e.g., yogurt with live and active cultures, Lactobacillus GG, Saccharomyces boulardii)
• Anticoagulants (e.g., warfarin and heparin)
• Vaccinations within 1 week prior to the pre-entry or study entry visits.

Sponsors & Collaborators

• Ruth M. Rothstein CORE Center: lead

Study Sites (1)

Ruth M. Rothstein CORE Center

Chicago, Illinois, 60612, United States

Location

MeSH Terms

Interventions

Lubiprostone

Intervention Hierarchy (Ancestors)

Alprostadil; Fatty Acids, Monounsaturated; Fatty Acids, Unsaturated; Fatty Acids; Lipids

Results Point of Contact

• Title: Dr. Gregory Huhn
• Organization: The Ruth M. Rothstein CORE Center

ghuhn@cookcountyhhs.org

312-572-4575

Study Officials

• Gregory Huhn, MD, MPHTM

  Ruth M. Rothstein CORE Center

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: Yes

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Attending Physician, Infectious Disease

Study Record Dates

• First Submitted: April 18, 2013
• First Posted: April 25, 2013
• Study Start: June 1, 2013
• Primary Completion: April 1, 2014
• Study Completion: February 1, 2016
• Last Updated: August 30, 2023
• Results First Posted: August 30, 2023

Record last verified: 2023-08

Locations

US (1)